S. Cook

发表

Changes in the balance of the tissue inhibitor of matrix metalloproteinases (TIMPs)-1 and -3 may promote keratocyte apoptosis in keratoconus.

A. Dick, F. J. Matthews, S. Cook, 2007, Experimental eye research.

MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b

D. Arnold, S. Narayanan, S. Cook, 2016, Neurology.

Herpes simplex virus in the eye.

S. Cook, 1992, The British journal of ophthalmology.

Measles vaccination does not prevent multiple sclerosis.

S. Cook, P. Dowling, S. Bansil, 1990, Neuroepidemiology.

Airway dynamics, oesophageal pressure and cough.

M. Lavietes, S. Smeltzer, S. Cook, 1998, The European respiratory journal.

Transcriptional map of the measles virus genome.

D. Kolakofsky, S. Cook, J. Crowley, 1986, The Journal of general virology.

Clinical evaluation of keratometry and computerised videokeratography: intraobserver and interobserver variability on normal and astigmatic corneas

S. Cook, J. Sparrow, C. H. Karabatsas, 1998, The British journal of ophthalmology.

Apoptotic death following Fas activation in human oligodendrocyte hybrid cultures

S. Cook, X. Ming, P. Dowling, 2002, Journal of neuroscience research.

Caspase-1 expression in multiple sclerosis plaques and cultured glial cells

S. Cook, X. Ming, P. Dowling, 2002, Journal of the Neurological Sciences.

Could Epstein-Barr virus or canine distemper virus cause multiple sclerosis?

S. Cook, J. Lincoln, K. Hankiewicz, 2008, Neurologic clinics.

Canine distemper virus L gene: sequence and comparison with related viruses.

S. Cook, M. Sidhu, S. Udem, 1993, Virology.

Corneal transplant rejection following influenza vaccination

S. Cook, M. Wertheim, D. Tole, 2006, British Journal of Ophthalmology.

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

P. Vermersch, G. Comi, G. Giovannoni, 2011, Multiple sclerosis.

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b

Dawn Langdon, Anthony L Traboulsee, Marcelo Kremenchutzky, 2019, Multiple sclerosis.

An overview of gene-epigenetic-environmental contributions to MS causation

S. Cook, J. Lincoln, 2009, Journal of the Neurological Sciences.

Steroid therapy in multiple sclerosis. Point of view.

S. Cook, P. Dowling, R. Troiano, 1987, Archives of neurology.

Comparison of keratometry and videokeratography after penetrating keratoplasty.

S. Cook, J. Sparrow, C. Karabatsas, 1998, Journal of refractive surgery.

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

P. Vermersch, G. Comi, G. Giovannoni, 2018, Multiple sclerosis.

EMERGING THERAPIES IN MULTIPLE SCLEROSIS

G. Comi, M. Filippi, L. Kappos, 2007 .

A New Perspective on Survival Outcomes in Multiple Sclerosis 3 Editorial Introduction: Life Expectancy in MS: Implications for Clinicians

S. Schippling, A. Reder, D. Langdon, 2012 .

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.

X. Montalban, G. Comi, G. Giovannoni, 2019, Multiple sclerosis and related disorders.

Spinocerebellar degeneration and cerebral hypomyelination in a family.

S. Cook, L. Wolansky, S. Chatkupt, 1995, American journal of medical genetics.

Effect of high–dose intravenous steriod administration on contrast‐enhancing computed tomographic scan lesions in multiple sclerosis

S. Cook, P. Dowling, R. Troiano, 1984 .

Remodelling the filtration bleb

J. Diamond, J. Morgan, S. Cook, 2002, The British journal of ophthalmology.

Proposed classification for topographic patterns seen after penetrating keratoplasty

S. Cook, J. Sparrow, C. H. Karabatsas, 1999, The British journal of ophthalmology.

Possible beneficial effect of high‐dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis

S. Cook, P. Dowling, V. V. Bosch, 1980, Neurology.

Clinical correlation with serum‐soluble interleukin‐2 receptor levels in Guillain‐Barré syndrome

S. Cook, A. Sheffet, S. Bansil, 1991, Neurology.

Peripheral Ulcerative Keratitis and Corneal Melt: A 10-Year Single Center Review With Historical Comparison

S. Cook, P. Georgoudis, D. Tole, 2014, Cornea.

Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy

M. Dalakas, S. Cook, Zie-Wie Chen, 1992, Journal of the Neurological Sciences.

Anti-GM1 IgA antibodies in Guillain-Barré syndrome

S. Cook, Zie-Wie Chen, A. Ilyas, 1992, Journal of Neuroimmunology.

Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis

S. Cook, C. Rohowsky-Kochan, D. Molinaro, 2000, Multiple sclerosis.

Trauma does not precipitate multiple sclerosis.

S. Cook, S. Cook, 2000, Archives of neurology.

Antibodies to GT1a ganglioside in patients with Guillain–Barré syndrome

S. Cook, T. Taki, S. Handa, 1998, Journal of Neuroimmunology.

Effects of Guillain-Barré sera containing antibodies against glycolipids in cultures of rat Schwann cells and sensory neurons

S. Cook, A. Ilyas, F. Mithen, 1992, Journal of the Neurological Sciences.

Antibodies to sulfated glycolipids in Guillain-Barré syndrome

M. Dalakas, S. Cook, L. Bielory, 1991, Journal of the Neurological Sciences.

Search for antibodies to neutral glycolipids in sera of patients with Guillain-Barré syndrome

S. Cook, Zie-Wie Chen, A. Ilyas, 1991, Journal of the Neurological Sciences.

Role of infection in Guillain‐Barré syndrome: Laboratory confirmation of herpesviruses in 41 cases

S. Cook, P. Dowling, 1981, Annals of neurology.

Landry-Guillain-Barré syndrome. A primary demyelinating disease.

H. Wiśniewski, R. Terry, S. Cook, 1969, Archives of neurology.

Respiratory function in multiple sclerosis. Utility of clinical assessment of respiratory muscle function.

J. Skurnick, M. Lavietes, S. Smeltzer, 1992, Chest.

Testing of an Index of Pulmonary Dysfunction in Multiple Sclerosis

M. Lavietes, S. Smeltzer, S. Cook, 1989, Nursing research.

Erythropoietin: A Potent Inducer of Peripheral Immuno/Inflammatory Modulation in Autoimmune EAE

R. Yuan, S. Cook, P. Dowling, 2008, PloS one.

Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis

G. Giovannoni, S. Cook, T. Leist, 2018, Multiple Sclerosis and Related Disorders.

Neutralizing antibodies to canine distemper and measles virus in multiple sclerosis

W. Russell, S. Cook, P. Dowling, 1979, Journal of the Neurological Sciences.

Measles virus nucleic acid sequences in human brain.

D. Kolakofsky, S. Cook, J. Prineas, 1986, Virus research.

Interleukin 17F level and interferon β response in patients with multiple sclerosis.

D. Goodin, M. Filippi, L. Kappos, 2013, JAMA neurology.

Circulating demyelinating factors in acute idiopathic polyneuropathy.

S. Cook, P. Dowling, J. Whitaker, 1971, Archives of neurology.

Approved drugs and their problems in patient care: Routes of administration and dosing

S. Cook, 2007, Journal of the Neurological Sciences.

Rate and types of fractures in corticosteroid‐treated multiple sclerosis patients

S. Cook, S. Bansil, R. Troiano, 1992, Neurology.

Autoimmune optic neuropathy with anticardiolipin antibody mimicking multiple sclerosis in a child.

W. Lambert, S. Cook, L. Bielory, 2003, American journal of ophthalmology.

DEATHS AFTER TOTAL LYMPHOID IRRADIATION FOR MULTIPLE SCLEROSIS

S. Cook, C. Rohowsky-Kochan, R. Troiano, 1989, The Lancet.

Total lymphoid irradiation for multiple sclerosis.

S. Cook, R. Troiano, M. Hafstein, 1988, International journal of radiation oncology, biology, physics.

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Abidemi K. Adeniji, P. Vermersch, G. Comi, 2018, Multiple sclerosis.

ABNORMAL MYELIN SHEATHS IN MULTIPLE SCLEROSIS: 105

S. Cook, J. Prineas, 1977 .

Corneal transplantation: how successful are we?

S. Cook, A. Waldock, 2000, The British journal of ophthalmology.

The effect of oral corticosteroid dosage on CT enhancing multiple sclerosis plaques

S. Cook, P. Dowling, R. Troiano, 1985, Journal of the Neurological Sciences.

Cladribine in aggressive forms of multiple sclerosis

S. Cook, L. Wolansky, D. Cadavid, 2007, European journal of neurology.

An ultrastructural study of experimental demyelination and remyelination. IV. Recurrent episodes and peripheral nervous system plaque formation in experimental allergic encephalomyelitis.

H. Wiśniewski, C. Raine, S. Cook, 1971, Laboratory investigation; a journal of technical methods and pathology.

Individual specific bias usage of HLA-DR antigens in the restriction of myelin basic protein-reactive T cell clones

S. Cook, C. Rohowsky-Kochan, Donna Eiman, 1993, Journal of the Neurological Sciences.

Multiple sclerosis in the Shetland Islands: an update

S. Cook, D. Poskanzer, P. Dowling, 1988, Acta neurologica Scandinavica.

Distemper and multiple sclerosis in Sitka, Alaska

S. Cook, P. Dowling, 1982, Annals of neurology.

Multiple sclerosis and distemper in Iceland 1966–1978

G. Gudmundsson, S. Cook, P. Dowling, 1980, Acta neurologica Scandinavica.

MULTIPLE SCLEROSIS AND CANINE DISTEMPER

W. Russell, S. Cook, P. Dowling, 1978, The Lancet.

Ocular herpes simplex virus reactivation in mice latently infected with latency-associated transcript mutants.

S. Cook, F. Sedarati, J. J. Doucet, 1991, Investigative ophthalmology & visual science.

Neurologic disorders associated with increased DNA synthesis in peripheral blood.

S. Cook, P. Dowling, 1968, Archives of neurology.

Free light chains in multiple sclerosis urine

P. Mehta, S. Cook, P. Coyle, 1998, Multiple sclerosis.

Does orally administered doxycycline reach the tear film?

A. Dick, S. Cook, V. Smith, 2008, British Journal of Ophthalmology.

Hypophosphatemia is Associated with the Serial Administration of Triple‐Dose Gadolinium to Patients for Brain MRI

S. Cook, M. Haghighi, L. Wolansky, 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

FINE STRUCTURAL ASPECTS OF DEMYELINATION IN VITRO. THE EFFECTS OF GUILLAIN‐BARRÉ SERUM

S. Cook, A. Hirano, P. Dowling, 1971, Journal of neuropathology and experimental neurology.

Anti-MAG IgM paraproteins from some patients with polyneuropathy associated with IgM paraproteinemia also react with sulfatide

M. Dalakas, S. Cook, A. Ilyas, 1992, Journal of Neuroimmunology.

Serum immunoglobulins in Guillain-Barré syndrome

S. Cook, P. Dowling, H. Chmel, 1970, Journal of the Neurological Sciences.

The ultrastructure of circulating immunocytes in Guillain‐Barré syndrome

S. Cook, A. Hirano, P. Dowling, 1970, Neurology.

Multiple Sclerosis: Pathogenesis and Treatment

S. Cook, P. Dowling, S. Bansil, 1994, Seminars in neurology.

Corneal transplant suture adjustment: authors’ reply

J. Diamond, D. Easty, S. Cook, 1999 .

Electrolysis-needle cauterization of corneal vessels in patients with lipid keratopathy.

S. Cook, M. Wertheim, D. Tole, 2007, Cornea.

No eye pad for corneal abrasion

S. Cook, J. Kirkpatrick, H. Hoh, 1993, Eye.

MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis

D. Arnold, Kunio Nakamura, J. Maranzano, 2017, Neurology.

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

P. Vermersch, G. Comi, G. Giovannoni, 2010, The New England journal of medicine.

Combination total lymphoid irradiation and low‐dose corticosteroid therapy for progressive multiple sclerosis

S. Cook, A. Sheffet, S. Bansil, 1995, Acta neurologica Scandinavica.

Cytomegalovirus cornplement fixation antibody in Guillain‐Barré syndrome

S. Cook, J. Menonna, P. Dowling, 1977, Neurology.

Effect of high-dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis.

S. Cook, R. Troiano, M. Hafstein, 1984, Annals of neurology.

Further evidence of a possible association between house dogs and multiple sclerosis

B. Natelson, S. Cook, B. Levin, 1978, Annals of neurology.

Intravenous gamma globulin in progressive MS

S. Cook, J. Oleske, L. Bielory, 1992, Acta neurologica Scandinavica.

Stability of visual outcome between 2 and 5 years following corneal transplantation in the UK

S. Cook, D. Tole, Mark N. A. Jones, 2017, British Journal of Ophthalmology.

Antiviral treatment following penetrating keratoplasty for herpetic keratitis

S. Cook, W. Armitage, D. Tole, 2011, Eye.

Long-term topical steroid treatment after penetrating keratoplasty in patients with pseudophakic bullous keratopathy.

S. Kaye, S. Cook, A. Ross, 2009, Ophthalmology.

Canine distemper terminal and intergenic non-protein coding nucleotide sequences: completion of the entire CDV genome sequence.

S. Cook, M. Sidhu, S. Udem, 1993, Virology.

Intraocular Lens Opacification After Descemet Stripping Automated Endothelial Keratoplasty

S. Cook, D. Tole, Muhammad A. Ahad, 2014, Cornea.

Combined interrupted and continuous versus single continuous adjustable suturing in penetrating keratoplasty: a prospective, randomized study of induced astigmatism during the first postoperative year.

J. Diamond, D. Easty, S. Cook, 1998, Ophthalmology.

Outcomes of same-sizing versus oversizing donor trephines in keratoconic patients undergoing first penetrating keratoplasty.

S. Kaye, S. Cook, P. Jaycock, 2008, Ophthalmology.

Surgical control of late postkeratoplasty astigmatism with or without the use of computerized video keratography: a prospective, randomized study.

J. Diamond, D. Easty, S. Cook, 1998, Ophthalmology.

The visual and refractive outcomes of combined and sequential penetrating keratoplasty, cataract extraction, and intraocular lens insertion

S. Kaye, S. Cook, W. Armitage, 2009, Eye.

MARGINAL CORNEAL DEGENERATION AND KERATOGLOBUS

S. Cook, C. H. K. Tsas, 1996 .

Topographic analysis in pellucid marginal corneal degeneration and keratoglobus

S. Cook, S. Cook, C. Karabatsas, 1996, Eye.

Acanthamoeba keratitis: risk factors and outcome.

D. Easty, S. Cook, C. Karabatsas, 1995, The British journal of ophthalmology.

Fibrin tissue‐filler glue for persistent epithelial defects

S. Cook, D. Tole, P. Sumich, 2003, Clinical and Experimental Ophthalmology.

Improved preservation of human corneal basement membrane following freezing of donor tissue for epikeratophakia.

D. Easty, S. Cook, R. Young, 1994, The British journal of ophthalmology.

donor tissue for epikeratophakia . basement membrane following freezing of Improved preservation of human corneal

D. Easty, S. Cook, R. Young, 2022 .

Herpes simplex virus: molecular biology and the possibility of corneal latency.

S. Cook, J. Hill, F. Ophth, 1991, Survey of ophthalmology.

Herpes simplex virus type 1 persistence and latency in cultured rabbit corneal epithelial cells, keratocytes, and endothelial cells.

S. Brown, S. Cook, S. M. Brown, 1986, The British journal of ophthalmology.

Long-Term Outcomes of High-Risk Keratoplasty in Patients Receiving Systemic Immunosuppression

S. Cook, D. Tole, S. Chow, 2015, Cornea.

Steroid drops after keratoplasty.

S. Cook, A. Ross, W. Armitage, 2012, Ophthalmology (Rochester, Minn.).

Latency-associated transcripts in corneas and ganglia of HSV-1 infected rabbits.

N. Maitland, S. Cook, C. Lynas, 1991, The British journal of ophthalmology.

Herpes simplex virus in the cornea; an ultrastructural study on viral reactivation.

S. Brown, S. Cook, K. Loeffler, 1986, Transactions of the ophthalmological societies of the United Kingdom.

Detection of herpes simplex virus type 1 gene expression in latently and productively infected mouse ganglia using the polymerase chain reaction.

N. Maitland, S. Cook, T. Hill, 1989, The Journal of general virology.

Total lymphoid irradiation in multiple sclerosis: Blood lymphocytes and clinical course

M. Lavenhar, S. Cook, P. Dowling, 1987, Annals of neurology.

EFFECT OF TOTAL LYMPHOID IRRADIATION IN CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS

M. Lavenhar, S. Cook, P. Dowling, 1986, The Lancet.

Evidence for multiple sclerosis as an infectious disease

S. Cook, P. Dowling, S. Bansil, 1995, Acta neurologica Scandinavica. Supplementum.

Recovery of herpes simplex virus from the corneas of experimentally infected rabbits.

S. Brown, S. Cook, S. K. Batra, 1987, The Journal of general virology.

Keratoconus: matrix metalloproteinase-2 activation and TIMP modulation.

F. J. Matthews, S. Cook, M. Majid, 2006, Biochimica et biophysica acta.

Different therapeutic approaches and outcome in the treatment of pterygium.

S. Cook, C. Karabatsas, G. Marsh, 1998, European journal of ophthalmology.

Antiviral drug sensitivity in ocular herpes simplex virus infection.

E. De Clercq, D. Easty, S. Cook, 1990, The British journal of ophthalmology.

Doxycycline—a role in ocular surface repair

S. Cook, V. Smith, V. A. Smith, 2004, British Journal of Ophthalmology.

Growth and characterization of rabbit corneal cells in vitro

S. Brown, S. Cook, D. Aitken, 1987, Graefe's Archive for Clinical and Experimental Ophthalmology.

Herpes simplex virus type 1 latency in rabbit corneal cells in vitro: reactivation and recombination following intratypic superinfection of long term cultures.

S. Brown, S. Cook, 1987, The Journal of general virology.

Nerve growth factor antibody stimulates reactivation of ocular herpes simplex virus type 1 in latently infected rabbits.

H. Thompson, S. Cook, B. Gebhardt, 1997, Journal of neurovirology.

ofHSV-1 infected rabbits

N. Maitland, S. Cook, C. Lynas, 2022 .

The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement

A. Dick, S. Cook, A. Ross, 2009, British Journal of Ophthalmology.

In vitro and in vivo ocular studies using herpes simplex virus types 1 and 2

S. Cook, 1988 .

Topical cyclosporin: a treatment for corneal graft rejection

S. Cook, A. Ross, 2008, Clinical & experimental ophthalmology.

The Guillain-Barré syndrome. Relationship of circulating immunocytes to disease activity.

S. Cook, P. Dowling, J. Whitaker, 1970, Archives of neurology.

Linkage analysis conditional on HLA status in a large North American pedigree supports the presence of a multiple sclerosis susceptibility locus on chromosome 12p12.

M. Rocchi, M. Devoto, C. Specchia, 2002, Human molecular genetics.

Multiple sclerosis and viruses

S. Cook, P. Dowling, 1980, Neurology.

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial

D. Goodin, M. Filippi, L. Kappos, 2016, Journal of Neurology.

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b

D. Goodin, M. Filippi, L. Kappos, 2015, Journal of Neurology.

Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis

P. Vermersch, G. Comi, P. Sørensen, 2012, Clinical Drug Investigation.

Variants of ST8SIA1 Are Associated with Risk of Developing Multiple Sclerosis

M. Devoto, J. Rubio, E. Vitale, 2008, PloS one.

The Epidemiology of Multiple Sclerosis : Clues to the Etiology of a Mysterious Disease

S. Cook, Stuart D. Cook, Stuart D. Cook, 2022 .

Serum sAPO‐1/Fas levels in multiple sclerosis

S. Cook, S. Bansil, C. Rohowsky-Kochan, 1997, Acta neurologica Scandinavica.

Thoracic syringomyelia and suspected multiple sclerosis: Cause and effect or coincidence?

S. Cook, M. Berger, J. A. Charles, 2004, Neurology.

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

S. Cook, A. Jotkowitz, J. Quinless, 2001, Neurology.

Guillain-Barré syndrome in Greater New York-New Jersey.

S. Cook, J. Menonna, P. Dowling, 1977, JAMA.

Multiple sclerosis and pregnancy.

S. Cook, P. Dowling, S. Bansil, 1994, Advances in neurology.

Decreased suppressor-inducer T lymphocytes in multiple sclerosis and other neurological diseases

S. Cook, J. Oleske, S. Bansil, 1990, Journal of Neuroimmunology.

T cell subsets and disease progression after total lymphoid irradiation in chronic progressive multiple sclerosis.

S. Cook, J. Oleske, P. Dowling, 1988, Journal of neurology, neurosurgery, and psychiatry.

The effect of total lymphoid irradiation and low-dose steroids on T lymphocyte populations in multiple sclerosis: correlation with clinical and MRI status

S. Cook, J. Oleske, L. Wolansky, 1997, Journal of the Neurological Sciences.

Beneficial effect of erythropoietin on experimental allergic encephalomyelitis

S. Elkabes, R. Yuan, S. Cook, 2004, Annals of neurology.

Measles virus L protein evidences elements of ancestral RNA polymerase.

S. Cook, J. Crowley, J. Menonna, 1988, Virology.

Sequence variability and function of measles virus 3' and 5' ends and intercistronic regions.

S. Cook, J. Crowley, J. Menonna, 1988, Virology.

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

Till F. M. Andlauer, F. Barkhof, M. Filippi, 2019, Multiple sclerosis.

Impaired interleukin-12 production in multiple sclerosis patients

S. Cook, M. Kahn, C. Rohowsky-Kochan, 1998, Multiple sclerosis.

Induction of autologous mixed lymphocyte culture responses by myelin basic protein-reactive T cell clones

S. Cook, J. Oleske, C. Rohowsky-Kochan, 1994, Journal of Neuroimmunology.

Multiple sclerosis: Immune mechanism and update on current therapies

S. Cook, S. Bansil, C. Rohowsky-Kochan, 1995, Annals of neurology.

A case–control study of risk factors for multiple sclerosis in Iran

A. Divani, A. Maghzi, Á. Alonso, 2011, Multiple sclerosis.

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.

D. Goodin, M. Filippi, L. Kappos, 2015, JAMA neurology.

Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis

S. Cook, Zie-Wie Chen, A. Ilyas, 2003, Journal of Neuroimmunology.

Elevated neopterin levels in Guillain-Barré syndrome. Further evidence of immune activation.

S. Cook, B. Singhal, S. Bansil, 1992, Archives of neurology.

Comparison between multiple sclerosis in India and the United States

M. Behari, S. Cook, B. Singhal, 1996, Neurology.

Serum levels of CXCL13 are elevated in active multiple sclerosis

J. Skurnick, S. Cook, L. Wolansky, 2009, Multiple sclerosis.

Increased free light chains in the urine from patients with multiple sclerosis

P. Mehta, S. Cook, P. Coyle, 1991, Neurology.

Expiratory training in multiple sclerosis.

M. Lavietes, S. Smeltzer, S. Cook, 1996, Archives of physical medicine and rehabilitation.

Dapsone induced haemolytic anaemia in patients treated for ocular cicatricial pemphigoid

S. Cook, M. Wertheim, D. Tole, 2006, British Journal of Ophthalmology.

A POSSIBLE ASSOCIATION BETWEEN HOUSE PETS AND MULTIPLE SCLEROSIS

P. Dowling, S. Cook, 1977, The Lancet.

Increased frequency of canine distemper virus‐specific antibodies in multiple sclerosis

S. Cook, A. Davidow, P. Dowling, 2020, Brain and behavior.

Household pets among veterans with multiple sclerosis and age-matched controls. Pilot survey.

S. Cook, P. Dowling, J. Norman, 1983, Archives of neurology.

A radioimmunoassay search for measles and distemper antigens in subacute sclerosing panencephalitis and multiple sclerosis brain tissues

W. Hall, S. Cook, J. Prineas, 1981, Journal of the Neurological Sciences.

MULTIPLE SCLEROSIS AND CANINE DISTEMPER IN ICELAND

S. Cook, P. Dowling, S. Jablon, 1979, The Lancet.

Clinical consequences of MRI activity in treated multiple sclerosis

J. Skurnick, S. Cook, L. Wolansky, 2011, Multiple sclerosis.

Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis

J. Goldstein, S. Cook, J. Boos, 1997, Journal of the Neurological Sciences.

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study

D. Goodin, J. Oger, G. Cutter, 2012, BMJ Open.

Quantitative functional measures in MS: What is a reliable change?

M. Mcdermott, A. Goodman, S. Cook, 2002, Neurology.

Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

J. Skurnick, S. Cook, J. Lincoln, 2009 .

A second case of Marburg’s variant of multiple sclerosis with vasculitis and extensive demyelination

S. Cook, J. Michaels, A. Pachner, 2011, Multiple sclerosis.

Gadoteridol in multiple sclerosis patients. A comparison of single and triple dose with immediate vs. delayed imaging.

S. Cook, L. Wolansky, S. Finden, 1998, Clinical imaging.

Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study

G. Comi, M. Filippi, L. Kappos, 2014, European Neurology.

Haematological profiles in patients treated with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96 week, phase III, double-blind, placebo-controlled trial

Viglietta, P. Vermersch, G. Comi, 2009 .

Triple‐Dose Versus Single‐Dose Gadoteridol in Multiple Sclerosis Patients

S. Cook, L. Wolansky, Leo J. Wolansky, 1994, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

P. Vermersch, P. Sørensen, G. Giovannoni, 2011, The Lancet Neurology.

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety

X. Montalban, G. Comi, G. Giovannoni, 2020, Drug Safety.

Clinical Trials Registry

S. Cook, 2006, New Jersey medicine : the journal of the Medical Society of New Jersey.

Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies

D. Goodin, M. Filippi, L. Kappos, 2012, Journal of Neuroinflammation.

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

D. Goodin, M. Filippi, L. Kappos, 2012, Multiple sclerosis.

MULTIPLE SCLEROSIS AND CANINE DISTEMPER ON KEY WEST, FLORIDA

S. Cook, P. Dowling, B. Blumberg, 1987, The Lancet.

Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

M. Sormani, F. Lublin, J. Simon, 2012, International journal of MS care.

Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course

M. Sormani, F. Lublin, J. Simon, 2016 .

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.

P. Vermersch, G. Comi, P. Sørensen, 2019, Multiple sclerosis and related disorders.

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

P. Vermersch, G. Comi, P. Sørensen, 2013, Journal of Neurology.

Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis

G. Comi, M. Filippi, L. Kappos, 2011, Multiple Sclerosis.

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study

Abidemi K. Adeniji, P. Vermersch, G. Comi, 2018, Therapeutic advances in neurological disorders.

Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies (P6.353)

Abidemi K. Adeniji, P. Vermersch, G. Comi, 2017 .

Association of Vitamin D LevelsWithMultiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1 b

D. Goodin, M. Filippi, L. Kappos, 2015 .

Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study.

P. Vermersch, G. Comi, G. Giovannoni, 2012, Multiple sclerosis and related disorders.

Handbook of Multiple Sclerosis

S. Cook, Stuart D. Cook, 1996 .

Spinal cord disease in children with HIV‐1 infection: a combined molecular biological and neuropathological study *

L. Epstein, S. Cook, J. Michaels, 1990, Neuropathology and applied neurobiology.

Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.095)

P. Vermersch, G. Comi, G. Giovannoni, 2016 .

Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.028)

P. Vermersch, G. Comi, G. Giovannoni, 2016 .

We should use magnetic resonance imaging to classify and monitor the course of multiple sclerosis.

J. Pollard, S. Cook, J. Lincoln, 2009, Archives of neurology.

Faculty Opinions recommendation of Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.

S. Cook, 2016 .

Impact of inflammation on brain volume in multiple sclerosis.

S. Cook, L. Wolansky, D. Cadavid, 2012, Archives of neurology.

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

Jeffrey A. Cohen, S. Cole, D. Arnold, 2002, Multiple sclerosis.

Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS)

P. Vermersch, G. Comi, G. Giovannoni, 2009 .

Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study

P. Vermersch, S. Greenberg, G. Comi, 2009 .

Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study

Viglietta, P. Vermersch, S. Greenberg, 2009 .

Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study

M. Filippi, L. Kappos, H. Hartung, 2013, Journal of Neurology.

Disease markers in acute multiple sclerosis.

S. Cook, P. Dowling, 1976, Archives of neurology.

Cause of death in MS : long-term own follow-UD of a randornised cohort , 21 years kter the start of the pivotal IFNP-lb study

D. Goodin, A. Reder, S. Cook, 2013 .

Advances in the PharDlacological and Neurological TreatDlent of Patients with Multiple Sclerosis

S. Cook, S. Barbieri-Berger, P. Dowling, 1993 .

Evidence for a Viral Etiology of Multiple Sclerosis

S. Cook, 2001 .

039 Rates of lymphopenia in years 1–4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets

P. Vermersch, G. Comi, P. Sørensen, 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

Fatal acute liver failure with hepatitis B virus infection during nataluzimab treatment in multiple sclerosis

S. Cook, A. Samanta, M. Hillen, 2015, Neurology: Neuroimmunology & Neuroinflammation.

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution

G. Comi, D. Arnold, D. Goodin, 2011, Neurology.

Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study.

P. Vermersch, G. Comi, P. Sørensen, 2012, Clinical drug investigation.

Myelin basic protein and multiple sclerosis

S. Cook, 1995, Journal of the Neurological Sciences.

Rheumatoid keratolysis 792 METHODS All patients with a diagnosis of RK at Bristol Eye

S. Cook, R. Malik, D. Tole, 2006 .

Immunoglobulin G subclass distribution of autoantibodies to gangliosides in patients with Guillain-Barre syndrome.

S. Cook, B. Singhal, Z. W. Chen, 2001, Research Communications in Molecular Pathology and Pharmacology.

Communications Serum 19 S and 7 S Demyelinating Antibodies in Multiple Sclerosis

S. Cook, Seung U. Kim, P. Dowling, 1968 .

Serum 19S and 7S demyelinating antibodies in multiple sclerosis.

S. U. Kim, S. Cook, P. Dowling, 1968, Journal of immunology.

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

P. Vermersch, P. Sørensen, G. Giovannoni, 2011, The Lancet Neurology.

Advancing treatment with interferon beta-1b (Betaferon®/Betaseron®) in the next decade

S. Cook, 2003, Journal of Neurology.

Erythropoietin: A Potent Inducer of Peripheral Immuno/Inflammatory Modulation in Autoimmune EAE

R. Yuan, S. Cook, P. Dowling, 2008, PloS one.

Updates in multiple sclerosis and related disorders: highlights of the 57th Annual Meeting of the American Academy of Neurology, April 9-16, 2005, Miami Beach, FL.

S. Cook, 2005, Reviews in neurological diseases.

Gray Matter Nucleus Hyperintensity After Monthly Triple-Dose Gadopentetate Dimeglumine With Long-term Magnetic Resonance Imaging

R. Munbodh, S. Cook, D. Bageac, 2020, Investigative radiology.

Does epstein-barr virus cause multiple sclerosis?

S. Cook, 2004, Reviews in neurological diseases.